{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:05:46Z","timestamp":1762625146161},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,15]]},"DOI":"10.7759\/cureus.48834","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T11:36:54Z","timestamp":1700048214000},"source":"Crossref","is-referenced-by-count":2,"title":["Polypharmacy and the In Silico Prediction of Potential Body Proteins Targeted by These Drugs Among Hospitalized COVID-19 Patients With Cytokine Storm"],"prefix":"10.7759","author":[{"given":"Ghazwan A","family":"Raouf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouad K","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muayad A","family":"Merza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2022.01.028","article-title":"Clinical update on COVID-19 for the emergency clinician: presentation and evaluation","volume":"54","author":"Long B","year":"2022","unstructured":"Long B, Carius BM, Chavez S, Liang SY, Brady WJ, Koyfman A, Gottlieb M. Clinical update on COVID-19 for the emergency clinician: presentation and evaluation. Am J Emerg Med. 2022, 54:46-57. 10.1016\/j.ajem.2022.01.028","journal-title":"Am J Emerg Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08921-5","article-title":"Risk and protective factors for COVID-19 morbidity, severity, and mortality","volume":"64","author":"Zhang JJ","year":"2023","unstructured":"Zhang JJ, Dong X, Liu GH, Gao YD. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol. 2023, 64:90-107. 10.1007\/s12016-022-08921-5","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang C","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1185330","article-title":"High mortality rates among COVID-19 intensive care patients in Iraq: insights from a retrospective cohort study at M\u00e9decins Sans Fronti\u00e8res supported hospital in Baghdad","volume":"11","author":"Malaeb R","year":"2023","unstructured":"Malaeb R, Haider A, Abdulateef M, et al.. High mortality rates among COVID-19 intensive care patients in Iraq: insights from a retrospective cohort study at M\u00e9decins Sans Fronti\u00e8res supported hospital in Baghdad. Front Public Health. 2023, 11:1185330. 10.3389\/fpubh.2023.1185330","journal-title":"Front Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-020-01415-w","article-title":"Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents","volume":"17","author":"Khadke S","year":"2020","unstructured":"Khadke S, Ahmed N, Ahmed N, et al.. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virol J. 2020, 17:154. 10.1186\/s12985-020-01415-w","journal-title":"Virol J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.06.017","article-title":"Cytokine storm induced by SARS-CoV-2","volume":"509","author":"Song P","year":"2020","unstructured":"Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020, 509:280-7. 10.1016\/j.cca.2020.06.017","journal-title":"Clin Chim Acta"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145027","article-title":"Metabolic reprogramming and epigenetic changes of vital organs in SARS-CoV-2-induced systemic toxicity","volume":"6","author":"Li S","year":"2021","unstructured":"Li S, Ma F, Yokota T, et al.. Metabolic reprogramming and epigenetic changes of vital organs in SARS-CoV-2-induced systemic toxicity. JCI Insight. 2021, 6:3-7. 10.1172\/jci.insight.145027","journal-title":"JCI Insight"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Yuan Y","year":"2023","unstructured":"Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol. 2023, 14:1125246. 10.3389\/fimmu.2023.1125246","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-023-01973-9","article-title":"An overview on the treatments and prevention against COVID-19","volume":"20","author":"Panahi Y","year":"2023","unstructured":"Panahi Y, Gorabi AM, Talaei S, Beiraghdar F, Akbarzadeh A, Tarhriz V, Mellatyar H. An overview on the treatments and prevention against COVID-19. Virol J. 2023, 20:23. 10.1186\/s12985-023-01973-9","journal-title":"Virol J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7150\/thno.49713","article-title":"Immunopathogenesis and treatment of cytokine storm in COVID-19","volume":"11","author":"Kim JS","year":"2021","unstructured":"Kim JS, Lee JY, Yang JW, et al.. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021, 11:316-29. 10.7150\/thno.49713","journal-title":"Theranostics"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013881.pub2","article-title":"Interleukin-6 blocking agents for treating COVID-19: a living systematic review","volume":"6","author":"Ghosn L","year":"2023","unstructured":"Ghosn L, Assi R, Evrenoglou T, et al.. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023, 6:CD013881. 10.1002\/14651858.CD013881.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2020.111639","article-title":"An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment","volume":"144","author":"Javorac D","year":"2020","unstructured":"Javorac D, Grahovac L, Mani\u0107 L, et al.. An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. Food Chem Toxicol. 2020, 144:111639. 10.1016\/j.fct.2020.111639","journal-title":"Food Chem Toxicol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2019.12.003","article-title":"Recognizing and managing polypharmacy in advanced illness","volume":"104","author":"Talebreza S","year":"2020","unstructured":"Talebreza S, McPherson ML. Recognizing and managing polypharmacy in advanced illness. Med Clin North Am. 2020, 104:405-13. 10.1016\/j.mcna.2019.12.003","journal-title":"Med Clin North Am"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon N","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017, 17:230. 10.1186\/s12877-017-0621-2","journal-title":"BMC Geriatr"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-022-00723-4","article-title":"The impact of polypharmacy on 30-day COVID-related mortality in nursing home residents: a multicenter retrospective cohort study","volume":"14","author":"Visser AG","year":"2023","unstructured":"Visser AG, Winkens B, Schols JM, Janknegt R, Spaetgens B. The impact of polypharmacy on 30-day COVID-related mortality in nursing home residents: a multicenter retrospective cohort study. Eur Geriatr Med. 2023, 14:51-7. 10.1007\/s41999-022-00723-4","journal-title":"Eur Geriatr Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060295","article-title":"Exploring the associations between polypharmacy and COVID-19-related hospitalisations and deaths: a population-based cohort study among older adults in Quebec, Canada","volume":"12","author":"Sirois C","year":"2022","unstructured":"Sirois C, Boiteau V, Chiu Y, Gilca R, Simard M. Exploring the associations between polypharmacy and COVID-19-related hospitalisations and deaths: a population-based cohort study among older adults in Quebec, Canada. BMJ Open. 2022, 12:e060295. 10.1136\/bmjopen-2021-060295","journal-title":"BMJ Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s41182-022-00456-x","article-title":"Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies","volume":"50","author":"Ghasemi H","year":"2022","unstructured":"Ghasemi H, Darvishi N, Salari N, Hosseinian-Far A, Akbari H, Mohammadi M. Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies. Trop Med Health. 2022, 50:60. 10.1186\/s41182-022-00456-x","journal-title":"Trop Med Health"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v22i4.65","article-title":"Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients","volume":"22","author":"Kilit TP","year":"2022","unstructured":"Kilit TP, \u00d6zyi\u011fit F, Erarslan S, Onba\u015f\u0131 K. Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients. Afr Health Sci. 2022, 22:597-606. 10.4314\/ahs.v22i4.65","journal-title":"Afr Health Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2022.03.016","article-title":"Potential for drug interactions and polypharmacy from treatment of COVID-19 in long-term care","volume":"23","author":"Blaszczyk AT","year":"2022","unstructured":"Blaszczyk AT, Sandlin K, Mirza S, Hernandez L, Bader H, Hall RG. Potential for drug interactions and polypharmacy from treatment of COVID-19 in long-term care. J Am Med Dir Assoc. 2022, 23:949-50. 10.1016\/j.jamda.2022.03.016","journal-title":"J Am Med Dir Assoc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2021.05.006","article-title":"Polypharmacy among COVID-19 patients: a systematic review","volume":"61","author":"Iloanusi S","year":"2021","unstructured":"Iloanusi S, Mgbere O, Essien EJ. Polypharmacy among COVID-19 patients: a systematic review. J Am Pharm Assoc (2003). 2021, 61:e14-25. 10.1016\/j.japh.2021.05.006","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S272908","article-title":"The double burden of the COVID-19 pandemic and polypharmacy on geriatric population - public health implications","volume":"16","author":"Rahman S","year":"2020","unstructured":"Rahman S, Singh K, Dhingra S, et al.. The double burden of the COVID-19 pandemic and polypharmacy on geriatric population - public health implications. Ther Clin Risk Manag. 2020, 16:1007-22. 10.2147\/TCRM.S272908","journal-title":"Ther Clin Risk Manag"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-01907-8","article-title":"Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study","volume":"19","author":"McKeigue PM","year":"2021","unstructured":"McKeigue PM, Kennedy S, Weir A, et al.. Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. BMC Med. 2021, 19:51. 10.1186\/s12916-021-01907-8","journal-title":"BMC Med"},{"key":"ref23","unstructured":"World Health Organization. Global surveillance for COVID-19 disease caused by human infection with novel coronavirus (\u200eCOVID-19)\u200e. interim guidance, 27 February. (2020). Accessed: November 14, 2023: https:\/\/iris.who.int\/handle\/10665\/331231."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218323","article-title":"Preliminary predictive criteria for COVID-19 cytokine storm","volume":"80","author":"Caricchio R","year":"2021","unstructured":"Caricchio R, Gallucci M, Dass C, et al.. Preliminary predictive criteria for COVID-19 cytokine storm. Ann Rheum Dis. 2021, 80:88-95. 10.1136\/annrheumdis-2020-218323","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30361","article-title":"Cross-sectional observational study on association of polypharmacy with health-related quality of life in patients with hypertension","volume":"14","author":"Paramba T","year":"2022","unstructured":"Paramba T, Zilate S. Cross-sectional observational study on association of polypharmacy with health-related quality of life in patients with hypertension. Cureus. 2022, 14:e30361. 10.7759\/cureus.30361","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02744.x","article-title":"Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems","volume":"63","author":"Viktil KK","year":"2007","unstructured":"Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007, 63:187-95. 10.1111\/j.1365-2125.2006.02744.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref27","article-title":"In-silico analysis on potential anti-SARS-CoV-2 protease agents by structure-based docking and cheminformatics","volume":"24","author":"Tiraihi T","year":"2021","unstructured":"Tiraihi T, Absalan A. In-silico analysis on potential anti-SARS-CoV-2 protease agents by structure-based docking and cheminformatics. MJMS. 2021, 24:11-25.","journal-title":"MJMS"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina A","year":"2019","unstructured":"Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019, 47:W357-64. 10.1093\/nar\/gkz382","journal-title":"Nucleic Acids Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3697498","article-title":"In silico identification of new anti-SARS-CoV-2 main protease (Mpro) molecules with pharmacokinetic properties from natural sources using molecular dynamics (MD) simulations and hierarchical virtual screening","volume":"2022","author":"Onyango H","year":"2022","unstructured":"Onyango H, Odhiambo P, Angwenyi D, Okoth P. In silico identification of new anti-SARS-CoV-2 main protease (Mpro) molecules with pharmacokinetic properties from natural sources using molecular dynamics (MD) simulations and hierarchical virtual screening. J Trop Med. 2022, 2022:3697498. 10.1155\/2022\/3697498","journal-title":"J Trop Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s43088-023-00406-4","article-title":"Identification of possible SARS-CoV-2 main protease inhibitors: in silico molecular docking and dynamic simulation studies","volume":"12","author":"Mukherjee A","year":"2023","unstructured":"Mukherjee A, Pandey KM, Ojha KK, Sahu SK. Identification of possible SARS-CoV-2 main protease inhibitors: in silico molecular docking and dynamic simulation studies. Beni-Suef Univ J Basic Appl Sci. 2023, 12:69-70. 10.1186\/s43088-023-00406-4","journal-title":"Beni-Suef Univ J Basic Appl Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/206566-polypharmacy-and-the-in-silico-prediction-of-potential-body-proteins-targeted-by-these-drugs-among-hospitalized-covid-19-patients-with-cytokine-storm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:41Z","timestamp":1707509501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/206566-polypharmacy-and-the-in-silico-prediction-of-potential-body-proteins-targeted-by-these-drugs-among-hospitalized-covid-19-patients-with-cytokine-storm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.48834","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,15]]}}}